Healthy Skepticism Library Topics: Generics

Generics

This page lists 55 references in the Main Healthy Skepticism Library relevant to Generics.

Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.

HSL6786
Shuchman M.
Delaying generic competition--corporate payoffs and the future of Plavix.
N Engl J Med 2006 Sep 28;355(13):1297-300
http://content.nejm.org/cgi/content/extract/355/13/1297

HSL6537
Silversides A.
Pharmacies receiving massive rebates from generic drug-makers.
CMAJ 2006 Aug 15;175(4):342
http://www.cmaj.ca/cgi/content/full/175/4/342

HSL6688
Owens J.
Generics pay-offs prohibited.
Nat Rev Drug Discov 2006 Aug 01;5(8):624

HSL6689
Harrison C.
Muddy waters for authorized generics.
Nat Rev Drug Discov 2006 Aug 01;5(8):624

HSL6690
Frantz S.
Pharma companies becoming more aggressive towards generics firms.
Nat Rev Drug Discov 2006 Aug 01;5(8):619-20

HSL5578
Klok RM, Boersma C, Oosterhuis I, Visser ST, DE Jong-VAN DEN Berg LT, Postma MJ.
Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands.
Aliment Pharmacol Ther 2006 Jun 1;23(11):1595-600
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2036.2006.02921.x

HSL5958
Vieira FS, Zucchi P.
[Price differences between generic and innovator medicines in Brazil].
Rev Saude Publica 2006 Jun 01;40(3):444-9
Link to source with long URL

HSL5622
Watson R.
EU companies can export generic versions of patented drugs to poor countries.
BMJ 2006 May 13;332(7550):1112
http://bmj.bmjjournals.com/cgi/content/full/332/7550/1112-a

HSL5932
Dunn JD, Cannon E, Mitchell MP, Curtiss FR.
Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system.
J Manag Care Pharm 2006 May 01;12(4):294-302

HSL5497
Dyer O.
Nine drug company chiefs are charged with conspiracy to defraud NHS.
BMJ 2006 Apr 15;332(7546):872
http://bmj.bmjjournals.com/cgi/content/full/332/7546/872-c

HSL5397
Werko L.
[The 'innovative' drug industry]
Lakartidningen 2006 Mar 15-21;103(11):857

HSL6107
Wick JY, Zanni GR.
Biogenerics: potential benefits and obstacles.
Consult Pharm 2006 Mar 01;21(3):208-12,

HSL5522
Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, Dirstine J, Avorn J, Asch SM.
The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.
Arch Intern Med 2006 Feb 13;166(3):332-7
http://archinte.ama-assn.org/cgi/content/full/166/3/332

HSL5754
Rickels K.
Consumer advertising can be misleading.
PLoS Med 2006 Feb 01;3(2):e119
Link to source with long URL

HSL5309
Drug-name game.
Consum Rep 2006 Jan;71(1):9

HSL5347
Wogart JP, Calcagnotto G.
Brazil's fight against AIDS and its implications for global health governance.
Healthc Q 2006;9(1):76-89

HSL4044
Zarocostas J.
WTO amendment on generic drugs draws mixed reaction.
BMJ 2005 Dec 17;331(7530):1421
Link to source with long URL

HSL5678
Bednarik J.
Does brand differentiate pharmaceuticals?
Neuro Endocrinol Lett 2005 Dec 01;26(6):635-52

HSL5265
Curtiss FR.
Who Needs XR, LA, SR, XL, ER, or CR?
J Manag Care Pharm 2005 Nov-Dec;11(9):772-3,

HSL5266
Hong SH, Shepherd MD, Scoones D, Wan TT.
Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
J Manag Care Pharm 2005 Nov-Dec;11(9):746-54

HSL5389
Fox JL.
Sandoz sues FDA over delay in first biogeneric approval.
Nat Biotechnol 2005 Nov;23(11):1327-8
http://www.nature.com/doifinder/10.1038/nbt1105-1327

HSL5054
Approval of drug marketed to African Americans raises political, economic issues. Study criticizes manufacturer for re-branding generic drug with race-specific indication.
Med Health 2005 Oct 24;59(38):1,

HSL5071
Iijima H, Kamei M, Koshimizu T, Shiragami M.
[Evaluation of information for generic drugs based on importance and necessity].
Yakugaku Zasshi 2005 Sep;125(9):739-47
Link to source with long URL

HSL4052
Havlir DV, Hammer SMPatents versus patients.
Antiretroviral therapy in India?
N Engl J Med 2005 Aug 25;353(8):749-51
http://content.nejm.org/cgi/content/extract/353/8/749

HSL5075
Davies A, Metcalfe S, Moodie P, McNee W.
PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists.
N Z Med J 2005 Aug 12;118(1220):U1621

HSL4179
Owens J.
Pharma allowed to make own genetics.
Nat Rev Drug Discov 2005 Jul 01;4(7):530

HSL4240
Jackson G.
Generic prescribing -- the chaos continues.
Int J Clin Pract 2005 Jun 01;59(6):618
Link to source with long URL

HSL5468
Rataboli PV, Garg A.
Confusing brand names: nightmare of medical profession.
J Postgrad Med 2005 Jan-Mar;51(1):13-6
Link to source with long URL

HSL2810
Iijima H, Kamei M, Koshimizu T, Shiragami M.
Objective evaluation of generic drug information.
Yakugaku Zasshi 2004 Jun;124(6):341-7
http://www.jstage.jst.go.jp/article/yakushi/124/6/124_341/_article

HSL230
Burton B.
Generics industry and doctors nervous over free trade deal.
BMJ 2004 May 15;328(7449):1158
http://bmj.bmjjournals.com/cgi/content/full/328/7449/1158-a

HSL5407
McCabe AR.
A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
Suffolk Univ Law Rev 2003;36(3):787-819

HSL2863
Hollis A.
The importance of being first: evidence from Canadian generic pharmaceuticals.
Health Econ 2002 Dec;11(8):723-34
Link to source with long URL

HSL2910
Health plans keeping drug cost increases in check with programs that promote generics.
Capitation Manag Rep. 2002 July 01;9(7):101-3
Link to source with long URL

HSL2743
Gold , A .
A drug by any other name
CMAJ 2001 Feb 20;164(4):464

HSL2744
Hoey , J .
A drug by any other name
CMAJ 2001 Feb 20;164(4):464

HSL2970
Hoey J.
A drug by any other name (response)
Canadian Medical Association Journal 2001 Feb 20;164(4):464

HSL5989
Rai AK.
The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era.
Univ Ill Law Rev 2001;2001(1):173-210

HSL728
Dong BJ, Hauck WW, Gambertoglio JG, Gee L, White JR, Bubp JL, Greenspan FS.
Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism.
JAMA 1997 Apr 16;277(15):1205-13

HSL826
Rapp MS.
Size of names in drug ads.
CMAJ 1995 Jan 15;152(2):158

HSL6279
Beazley GP.
Size of names in drug ads
Canadian Medical Association Journal 1994;151:1113

HSL6285
Chetley A.
Generic embarrassment
Lancet 1994;343:1089-1090

HSL4818
Ferner RE, Scott DK.
The nature and content of advertisements for medicines
British Journal of Clinical Pharmacology 1992;34:158P

HSL4546
Lexchin J.
Disinformation from pharmaceutical company representatives
Canadian Medical Association Journal 1990;143:370

HSL4566
Pye J.
“Disinformation” from pharmaceutical company representatives
Canadian Medical Association Journal 1990;142:1178

HSL4469
Logarta JD.
Generics revisited: an overdose of expectations
Drug Monitor 1989 Apr;4(4):49-54

HSL4004
Hemminki E.
Commercial information on drugs: confusing the physician?
Journal of Drug Issues 1988;18:245-257

HSL4007
Hurwitz MA, Caves RE.
Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals
Journal of Law and Economics 1988;31:299-320

HSL3868
Bower AD, Burkett GL.
Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices.
J Fam Pract 1987 Jun;24(6):612-6

HSL3619
Bansinath M, Sequeira RP, Shukla VK, Mathur VS.
Brand versus generic prescribing: a perspective of the Indian cardiologists' viewpoint.
Int J Clin Pharmacol Ther Toxicol 1984 Jun;22(6):279-83

HSL3632
Hemminki E, Enlund H, Hellevuo K, Laurila R, Turakka H.
Trade names and generic names: Problems for prescribing physicians
Scandinavian Journal of Primary Health Care 1984;2:84-87

HSL3581
Generali JA, Hogan L.
A comparison of pharmaceutical manufacturers as a source of drug information to a telephone inquiry: generic vs brand.
Drug Inf J 1983;17(3):195-204

HSL3593
Quraeshi ZA, Luqmani M, Malhotra N.
Brands or generics: the dilemma of pharmaceutical marketing in a developing country.
J Health Care Mark 1983 Fal;3(4):27-37

HSL3518
Oppenheim GL, Erickson SH, Ashworth C.
The family physician's knowledge of the cost of prescribed drugs.
J Fam Pract 1981 Jun;12(6):1027-30

HSL3432
Martin RW.
Diuretic equivalence of frusemide preparations
New Zealand Medical Journal 1979;90:209

HSL3244
Knight JL, Baumgartner RP.
Quality control information—its availability from pharmaceutical manufacturers
Hospital Formulary Management 1974;9(9):35, 37, 40-42, 50

		Healthy Skepticism Countering misleading drug promotion Home \| About us \| Site info \| Contact us \| Links \| Other What's new \| AdWatch \| HS Int News \| Library \| Fora
Home - www.healthyskepticism.org > library > topics: Generics : Updated 23 August, 2005
For you Free Updates Can we help you? Help the cause Join in Subscribe to Healthy Skepticism Updates Feedback If you like our work please tell others. If not, please tell us.		Generics This page lists 55 references in the Main Healthy Skepticism Library relevant to Generics. Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text. HSL6786 Shuchman M. Delaying generic competition--corporate payoffs and the future of Plavix. N Engl J Med 2006 Sep 28;355(13):1297-300 http://content.nejm.org/cgi/content/extract/355/13/1297 HSL6537 Silversides A. Pharmacies receiving massive rebates from generic drug-makers. CMAJ 2006 Aug 15;175(4):342 http://www.cmaj.ca/cgi/content/full/175/4/342 HSL6688 Owens J. Generics pay-offs prohibited. Nat Rev Drug Discov 2006 Aug 01;5(8):624 HSL6689 Harrison C. Muddy waters for authorized generics. Nat Rev Drug Discov 2006 Aug 01;5(8):624 HSL6690 Frantz S. Pharma companies becoming more aggressive towards generics firms. Nat Rev Drug Discov 2006 Aug 01;5(8):619-20 HSL5578 Klok RM, Boersma C, Oosterhuis I, Visser ST, DE Jong-VAN DEN Berg LT, Postma MJ. Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands. Aliment Pharmacol Ther 2006 Jun 1;23(11):1595-600 http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2036.2006.02921.x HSL5958 Vieira FS, Zucchi P. [Price differences between generic and innovator medicines in Brazil]. Rev Saude Publica 2006 Jun 01;40(3):444-9 Link to source with long URL HSL5622 Watson R. EU companies can export generic versions of patented drugs to poor countries. BMJ 2006 May 13;332(7550):1112 http://bmj.bmjjournals.com/cgi/content/full/332/7550/1112-a HSL5932 Dunn JD, Cannon E, Mitchell MP, Curtiss FR. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. J Manag Care Pharm 2006 May 01;12(4):294-302 HSL5497 Dyer O. Nine drug company chiefs are charged with conspiracy to defraud NHS. BMJ 2006 Apr 15;332(7546):872 http://bmj.bmjjournals.com/cgi/content/full/332/7546/872-c HSL5397 Werko L. [The 'innovative' drug industry] Lakartidningen 2006 Mar 15-21;103(11):857 HSL6107 Wick JY, Zanni GR. Biogenerics: potential benefits and obstacles. Consult Pharm 2006 Mar 01;21(3):208-12, HSL5522 Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, Dirstine J, Avorn J, Asch SM. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 2006 Feb 13;166(3):332-7 http://archinte.ama-assn.org/cgi/content/full/166/3/332 HSL5754 Rickels K. Consumer advertising can be misleading. PLoS Med 2006 Feb 01;3(2):e119 Link to source with long URL HSL5309 Drug-name game. Consum Rep 2006 Jan;71(1):9 HSL5347 Wogart JP, Calcagnotto G. Brazil's fight against AIDS and its implications for global health governance. Healthc Q 2006;9(1):76-89 HSL4044 Zarocostas J. WTO amendment on generic drugs draws mixed reaction. BMJ 2005 Dec 17;331(7530):1421 Link to source with long URL HSL5678 Bednarik J. Does brand differentiate pharmaceuticals? Neuro Endocrinol Lett 2005 Dec 01;26(6):635-52 HSL5265 Curtiss FR. Who Needs XR, LA, SR, XL, ER, or CR? J Manag Care Pharm 2005 Nov-Dec;11(9):772-3, HSL5266 Hong SH, Shepherd MD, Scoones D, Wan TT. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration. J Manag Care Pharm 2005 Nov-Dec;11(9):746-54 HSL5389 Fox JL. Sandoz sues FDA over delay in first biogeneric approval. Nat Biotechnol 2005 Nov;23(11):1327-8 http://www.nature.com/doifinder/10.1038/nbt1105-1327 HSL5054 Approval of drug marketed to African Americans raises political, economic issues. Study criticizes manufacturer for re-branding generic drug with race-specific indication. Med Health 2005 Oct 24;59(38):1, HSL5071 Iijima H, Kamei M, Koshimizu T, Shiragami M. [Evaluation of information for generic drugs based on importance and necessity]. Yakugaku Zasshi 2005 Sep;125(9):739-47 Link to source with long URL HSL4052 Havlir DV, Hammer SMPatents versus patients. Antiretroviral therapy in India? N Engl J Med 2005 Aug 25;353(8):749-51 http://content.nejm.org/cgi/content/extract/353/8/749 HSL5075 Davies A, Metcalfe S, Moodie P, McNee W. PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists. N Z Med J 2005 Aug 12;118(1220):U1621 HSL4179 Owens J. Pharma allowed to make own genetics. Nat Rev Drug Discov 2005 Jul 01;4(7):530 HSL4240 Jackson G. Generic prescribing -- the chaos continues. Int J Clin Pract 2005 Jun 01;59(6):618 Link to source with long URL HSL5468 Rataboli PV, Garg A. Confusing brand names: nightmare of medical profession. J Postgrad Med 2005 Jan-Mar;51(1):13-6 Link to source with long URL HSL2810 Iijima H, Kamei M, Koshimizu T, Shiragami M. Objective evaluation of generic drug information. Yakugaku Zasshi 2004 Jun;124(6):341-7 http://www.jstage.jst.go.jp/article/yakushi/124/6/124_341/_article HSL230 Burton B. Generics industry and doctors nervous over free trade deal. BMJ 2004 May 15;328(7449):1158 http://bmj.bmjjournals.com/cgi/content/full/328/7449/1158-a HSL5407 McCabe AR. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. Suffolk Univ Law Rev 2003;36(3):787-819 HSL2863 Hollis A. The importance of being first: evidence from Canadian generic pharmaceuticals. Health Econ 2002 Dec;11(8):723-34 Link to source with long URL HSL2910 Health plans keeping drug cost increases in check with programs that promote generics. Capitation Manag Rep. 2002 July 01;9(7):101-3 Link to source with long URL HSL2743 Gold , A . A drug by any other name CMAJ 2001 Feb 20;164(4):464 HSL2744 Hoey , J . A drug by any other name CMAJ 2001 Feb 20;164(4):464 HSL2970 Hoey J. A drug by any other name (response) Canadian Medical Association Journal 2001 Feb 20;164(4):464 HSL5989 Rai AK. The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era. Univ Ill Law Rev 2001;2001(1):173-210 HSL728 Dong BJ, Hauck WW, Gambertoglio JG, Gee L, White JR, Bubp JL, Greenspan FS. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA 1997 Apr 16;277(15):1205-13 HSL826 Rapp MS. Size of names in drug ads. CMAJ 1995 Jan 15;152(2):158 HSL6279 Beazley GP. Size of names in drug ads Canadian Medical Association Journal 1994;151:1113 HSL6285 Chetley A. Generic embarrassment Lancet 1994;343:1089-1090 HSL4818 Ferner RE, Scott DK. The nature and content of advertisements for medicines British Journal of Clinical Pharmacology 1992;34:158P HSL4546 Lexchin J. Disinformation from pharmaceutical company representatives Canadian Medical Association Journal 1990;143:370 HSL4566 Pye J. “Disinformation” from pharmaceutical company representatives Canadian Medical Association Journal 1990;142:1178 HSL4469 Logarta JD. Generics revisited: an overdose of expectations Drug Monitor 1989 Apr;4(4):49-54 HSL4004 Hemminki E. Commercial information on drugs: confusing the physician? Journal of Drug Issues 1988;18:245-257 HSL4007 Hurwitz MA, Caves RE. Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals Journal of Law and Economics 1988;31:299-320 HSL3868 Bower AD, Burkett GL. Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. J Fam Pract 1987 Jun;24(6):612-6 HSL3619 Bansinath M, Sequeira RP, Shukla VK, Mathur VS. Brand versus generic prescribing: a perspective of the Indian cardiologists' viewpoint. Int J Clin Pharmacol Ther Toxicol 1984 Jun;22(6):279-83 HSL3632 Hemminki E, Enlund H, Hellevuo K, Laurila R, Turakka H. Trade names and generic names: Problems for prescribing physicians Scandinavian Journal of Primary Health Care 1984;2:84-87 HSL3581 Generali JA, Hogan L. A comparison of pharmaceutical manufacturers as a source of drug information to a telephone inquiry: generic vs brand. Drug Inf J 1983;17(3):195-204 HSL3593 Quraeshi ZA, Luqmani M, Malhotra N. Brands or generics: the dilemma of pharmaceutical marketing in a developing country. J Health Care Mark 1983 Fal;3(4):27-37 HSL3518 Oppenheim GL, Erickson SH, Ashworth C. The family physician's knowledge of the cost of prescribed drugs. J Fam Pract 1981 Jun;12(6):1027-30 HSL3432 Martin RW. Diuretic equivalence of frusemide preparations New Zealand Medical Journal 1979;90:209 HSL3244 Knight JL, Baumgartner RP. Quality control information—its availability from pharmaceutical manufacturers Hospital Formulary Management 1974;9(9):35, 37, 40-42, 50
881 visits to this page since 1 January 2007		Home \| Add to Favourites \| Site Map \| Credits \| Privacy Policy \| Update Policy \| Feedback Policy

Countering misleading drug promotion

Generics